<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>73</patient-age><report-id>CA-UCBSA-069937</report-id><gender>male</gender><reactions><reaction>STAGE 1E DIFFUSE LARGE B-CELL LYMPHOMA </reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>CIMZIA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>FOLIC ACID</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>METHOTREXATE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>SYNTHROID</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>VITAMIN D</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Rheumatoid arthritis</indication><indication>Vitamin supplementation</indication><indication>Hypothyroidism</indication></indications><patient-age>73</patient-age><outcomes/><country>Canada</country><geo/></meta><original><ichicsr lang="en" xmlns="">
    <ichicsrmessageheader>
        <messagetype>ichicsr</messagetype>
        <messageformatversion>2.1</messageformatversion>
        <messageformatrelease>2.0</messageformatrelease>
        <messagenumb>UCBPHAPROD-92321-320691</messagenumb>
        <messagesenderidentifier>UCBPVGPRD</messagesenderidentifier>
        <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
        <messagedateformat>204</messagedateformat>
        <messagedate>20130125162605</messagedate>
    </ichicsrmessageheader>
    <safetyreport>
        <safetyreportversion>2</safetyreportversion>
        <safetyreportid>CA-UCBSA-069937</safetyreportid>
        <primarysourcecountry>CA</primarysourcecountry>
        <occurcountry>CA</occurcountry>
        <transmissiondateformat>102</transmissiondateformat>
        <transmissiondate>2013-01-25</transmissiondate>
        <reporttype>2</reporttype>
        <serious code="1">Yes</serious>
        <seriousnessother>1</seriousnessother>
        <receivedateformat>102</receivedateformat>
        <receivedate>2012-10-26</receivedate>
        <receiptdateformat>102</receiptdateformat>
        <receiptdate>2013-01-16</receiptdate>
        <additionaldocument>2</additionaldocument>
        <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
        <companynumb>CA-UCBSA-069937</companynumb>
        <primarysource>
            <reportergivename>NANCY</reportergivename>
            <reporterfamilyname>BROCKEST</reporterfamilyname>
            <reportercountry>CA</reportercountry>
            <qualification code="3">Other Health Professional</qualification>
            <studyname>#Solutions Program Canada Cimzia</studyname>
            <sponsorstudynumb>CERTOL01_Solutions Pr Canada</sponsorstudynumb>
            <observestudytype>3</observestudytype>
        </primarysource>
        <sender>
            <sendertype>1</sendertype>
            <senderorganization>UCB</senderorganization>
            <sendertitle>Dr.</sendertitle>
            <sendergivename>Peter</sendergivename>
            <senderfamilyname>Verdru</senderfamilyname>
            <senderstreetaddress>1950 Lake Park Drive</senderstreetaddress>
            <sendercity>Smyrna</sendercity>
            <senderstate>GA</senderstate>
            <senderpostcode>30080</senderpostcode>
            <sendercountrycode>US</sendercountrycode>
            <sendertel>9197673193</sendertel>
            <sendertelcountrycode>1</sendertelcountrycode>
            <senderfax>9197673174</senderfax>
            <senderfaxcountrycode>1</senderfaxcountrycode>
            <senderemailaddress>peter.verdru@ucb.com</senderemailaddress>
        </sender>
        <receiver>
            <receivertype>2</receivertype>
            <receiverorganization>FDA</receiverorganization>
            <receiverdepartment>Office of Surveillance and Epidemiology</receiverdepartment>
            <receivertitle>Mr.</receivertitle>
            <receivergivename>Roger</receivergivename>
            <receiverfamilyname>Goetsch</receiverfamilyname>
            <receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
            <receivercity>Landover</receivercity>
            <receiverstate>MD</receiverstate>
            <receiverpostcode>20785</receiverpostcode>
            <receivercountrycode>US</receivercountrycode>
            <receivertel>3019189580</receivertel>
            <receivertelextension>194</receivertelextension>
            <receivertelcountrycode>1</receivertelcountrycode>
            <receiverfax>3019183134</receiverfax>
            <receiverfaxcountrycode>1</receiverfaxcountrycode>
            <receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
        </receiver>
        <patient>
            <patientinitial>MG</patientinitial>
            <patientbirthdateformat>102</patientbirthdateformat>
            <patientbirthdate>19390208</patientbirthdate>
            <patientonsetage>73</patientonsetage>
            <patientonsetageunit>801</patientonsetageunit>
            <patientweight>74.09</patientweight>
            <patientheight>167</patientheight>
            <patientsex code="1">Male</patientsex>
            <medicalhistoryepisode>
                <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
                <patientepisodename>Seronegative arthritis</patientepisodename>
                <patientmedicalcontinue>3</patientmedicalcontinue>
            </medicalhistoryepisode>
            <medicalhistoryepisode>
                <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
                <patientepisodename>Hypothyroidism</patientepisodename>
                <patientmedicalcontinue>3</patientmedicalcontinue>
            </medicalhistoryepisode>
            <medicalhistoryepisode>
                <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
                <patientepisodename>Nodal osteoarthritis</patientepisodename>
                <patientmedicalcontinue>3</patientmedicalcontinue>
            </medicalhistoryepisode>
            <medicalhistoryepisode>
                <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
                <patientepisodename>Nodal osteoarthritis</patientepisodename>
                <patientmedicalcontinue>3</patientmedicalcontinue>
            </medicalhistoryepisode>
            <medicalhistoryepisode>
                <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
                <patientepisodename>Knee arthroplasty</patientepisodename>
                <patientmedicalstartdateformat>610</patientmedicalstartdateformat>
                <patientmedicalstartdate>200711</patientmedicalstartdate>
                <patientmedicalcontinue>3</patientmedicalcontinue>
            </medicalhistoryepisode>
            <patientpastdrugtherapy>
                <patientdrugname>ENBREL</patientdrugname>
                <patientdrugstartdateformat>610</patientdrugstartdateformat>
                <patientdrugstartdate>201106</patientdrugstartdate>
                <patientdrugenddateformat>610</patientdrugenddateformat>
                <patientdrugenddate>201205</patientdrugenddate>
            </patientpastdrugtherapy>
            <reaction>
                <primarysourcereaction>STAGE 1E DIFFUSE LARGE B-CELL LYMPHOMA </primarysourcereaction>
                <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
                <reactionmeddrallt>10012823</reactionmeddrallt>
                <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
                <reactionmeddrapt>10012823</reactionmeddrapt>
                <reactionstartdateformat>102</reactionstartdateformat>
                <reactionstartdate>20121023</reactionstartdate>
                <reactionfirsttime>165</reactionfirsttime>
                <reactionfirsttimeunit>804</reactionfirsttimeunit>
                <reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
            </reaction>
            <drug>
                <drugcharacterization code="1">suspsect</drugcharacterization>
                <medicinalproduct>CIMZIA</medicinalproduct>
                <drugauthorizationnumb>125,160</drugauthorizationnumb>
                <drugstructuredosagenumb>200</drugstructuredosagenumb>
                <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
                <drugseparatedosagenumb>1</drugseparatedosagenumb>
                <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
                <drugintervaldosagedefinition code="803">Week</drugintervaldosagedefinition>
                <drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
                <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
                <drugindication>Rheumatoid arthritis</drugindication>
                <drugstartdateformat>102</drugstartdateformat>
                <drugstartdate>2012-06-16</drugstartdate>
                <drugstartperiod>165</drugstartperiod>
                <drugstartperiodunit>804</drugstartperiodunit>
                <actiondrug code="4">Dose not changed</actiondrug>
                <activesubstance>
                    <activesubstancename>CERTOLIZUMAB PEGOL</activesubstancename>
                </activesubstance>
                <drugreactionrelatedness>
                    <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
                    <drugreactionasses>Diffuse large B-cell lymphoma stage I</drugreactionasses>
                    <drugassessmentsource>Company</drugassessmentsource>
                    <drugassessmentmethod>IN HOUSE SCALE</drugassessmentmethod>
                    <drugresult>RELATED</drugresult>
                </drugreactionrelatedness>
            </drug>
            <drug>
                <drugcharacterization code="1">suspsect</drugcharacterization>
                <medicinalproduct>CIMZIA</medicinalproduct>
                <drugauthorizationnumb>125,160</drugauthorizationnumb>
                <drugstructuredosagenumb>400</drugstructuredosagenumb>
                <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
                <drugseparatedosagenumb>1</drugseparatedosagenumb>
                <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
                <drugintervaldosagedefinition code="803">Week</drugintervaldosagedefinition>
                <drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
                <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
                <drugindication>Rheumatoid arthritis</drugindication>
                <drugstartdateformat>102</drugstartdateformat>
                <drugstartdate>2012-05-12</drugstartdate>
                <drugstartperiod>165</drugstartperiod>
                <drugstartperiodunit>804</drugstartperiodunit>
                <drugenddateformat>102</drugenddateformat>
                <drugenddate>2012-06-02</drugenddate>
                <drugtreatmentduration>22</drugtreatmentduration>
                <drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
                <actiondrug code="4">Dose not changed</actiondrug>
                <activesubstance>
                    <activesubstancename>CERTOLIZUMAB PEGOL</activesubstancename>
                </activesubstance>
                <drugreactionrelatedness>
                    <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
                    <drugreactionasses>Diffuse large B-cell lymphoma stage I</drugreactionasses>
                    <drugassessmentsource>Company</drugassessmentsource>
                    <drugassessmentmethod>IN HOUSE SCALE</drugassessmentmethod>
                    <drugresult>RELATED</drugresult>
                </drugreactionrelatedness>
            </drug>
            <drug>
                <drugcharacterization code="2">concomitant</drugcharacterization>
                <medicinalproduct>FOLIC ACID</medicinalproduct>
                <drugstructuredosagenumb>1</drugstructuredosagenumb>
                <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
                <drugseparatedosagenumb>1</drugseparatedosagenumb>
                <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
                <drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
                <drugdosagetext>6/7</drugdosagetext>
                <drugadministrationroute code="048">Oral</drugadministrationroute>
                <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
                <drugindication>Vitamin supplementation</drugindication>
                <drugstartdateformat>610</drugstartdateformat>
                <drugstartdate>2009-06-01</drugstartdate>
                <actiondrug code="4">Dose not changed</actiondrug>
                <activesubstance>
                    <activesubstancename>FOLIC ACID</activesubstancename>
                </activesubstance>
            </drug>
            <drug>
                <drugcharacterization code="2">concomitant</drugcharacterization>
                <medicinalproduct>METHOTREXATE</medicinalproduct>
                <drugstructuredosagenumb>25</drugstructuredosagenumb>
                <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
                <drugseparatedosagenumb>1</drugseparatedosagenumb>
                <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
                <drugintervaldosagedefinition code="803">Week</drugintervaldosagedefinition>
                <drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
                <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
                <drugindication>Rheumatoid arthritis</drugindication>
                <drugstartdateformat>610</drugstartdateformat>
                <drugstartdate>2009-06-01</drugstartdate>
                <actiondrug code="4">Dose not changed</actiondrug>
                <activesubstance>
                    <activesubstancename>METHOTREXATE</activesubstancename>
                </activesubstance>
            </drug>
            <drug>
                <drugcharacterization code="2">concomitant</drugcharacterization>
                <medicinalproduct>SYNTHROID</medicinalproduct>
                <drugstructuredosagenumb>150</drugstructuredosagenumb>
                <drugstructuredosageunit code="004">micrograms</drugstructuredosageunit>
                <drugseparatedosagenumb>1</drugseparatedosagenumb>
                <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
                <drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
                <drugdosagetext>ONCE DAILY FOR 3 DAYS</drugdosagetext>
                <drugadministrationroute code="048">Oral</drugadministrationroute>
                <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
                <drugindication>Hypothyroidism</drugindication>
                <actiondrug code="4">Dose not changed</actiondrug>
                <activesubstance>
                    <activesubstancename>LEVOTHYROXINE SODIUM</activesubstancename>
                </activesubstance>
            </drug>
            <drug>
                <drugcharacterization code="2">concomitant</drugcharacterization>
                <medicinalproduct>SYNTHROID</medicinalproduct>
                <drugstructuredosagenumb>175</drugstructuredosagenumb>
                <drugstructuredosageunit code="004">micrograms</drugstructuredosageunit>
                <drugseparatedosagenumb>1</drugseparatedosagenumb>
                <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
                <drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
                <drugdosagetext>ONCE DAILY FOR 4 DAYS</drugdosagetext>
                <drugadministrationroute code="048">Oral</drugadministrationroute>
                <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
                <drugindication>Hypothyroidism</drugindication>
                <actiondrug code="4">Dose not changed</actiondrug>
                <activesubstance>
                    <activesubstancename>LEVOTHYROXINE SODIUM</activesubstancename>
                </activesubstance>
            </drug>
            <drug>
                <drugcharacterization code="2">concomitant</drugcharacterization>
                <medicinalproduct>VITAMIN D</medicinalproduct>
                <drugstructuredosagenumb>1000</drugstructuredosagenumb>
                <drugstructuredosageunit code="025"/>
                <drugseparatedosagenumb>1</drugseparatedosagenumb>
                <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
                <drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
                <drugadministrationroute code="048">Oral</drugadministrationroute>
                <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
                <drugindication>Vitamin supplementation</drugindication>
                <actiondrug code="4">Dose not changed</actiondrug>
                <activesubstance>
                    <activesubstancename>ERGOCALCIFEROL</activesubstancename>
                </activesubstance>
            </drug>
            <summary>
                <narrativeincludeclinical>This non interventional study report from <Semaphore x="360965" class="Medicine" value="Cimzia" score="0.74" ID="282644">Cimzia </Semaphore>solution program was received by UCB (Affiliate ID: CAN_AE_2012_CZP_452) on 26-Oct 2012 from a <Semaphore x="2326562" class="Occupation" value="Nurse" score="1.00" ID="C20821">registered <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore></Semaphore>via medical representative.This case <Semaphore x="1805433" class="Procedure" value="Concern About Finances" score="1.00" ID="C104604">concerns </Semaphore>a 73-year old male subject from Canada with medical history of HLA B27 <Semaphore x="3245971" class="MedDRA LLT" value="Seronegative arthritis" score="1.00" ID="10062164">seronegative <Semaphore x="1547603" class="Disease or Finding" value="Arthropathy" score="1.00" ID="C35760">arthropathy</Semaphore></Semaphore>, <Semaphore x="2042024" class="Disease or Finding" value="Hypothyroidism" score="1.00" ID="C26800">hypothyroidism</Semaphore>, <Semaphore x="3144586" class="MedDRA LLT" value="Nodal osteoarthritis" score="1.00" ID="10029469"><Semaphore x="2011283" class="Disease or Finding" value="Heberden's Node" score="1.00" ID="C34671">Heberden<Semaphore x="3144586" class="MedDRA LLT" value="Nodal osteoarthritis" score="1.00" ID="10029469">'s <Semaphore x="3144586" class="MedDRA LLT" value="Nodal osteoarthritis" score="1.00" ID="10029469">nodes</Semaphore></Semaphore></Semaphore>
     <Semaphore x="3144586" class="MedDRA LLT" value="Nodal osteoarthritis" score="1.00" ID="10029469">
      , <Semaphore x="3144586" class="MedDRA LLT" value="Nodal osteoarthritis" score="1.00" ID="10029469">Bouchard</Semaphore>'s </Semaphore><Semaphore x="2311429" class="AnatomicStructure" value="Node" score="1.00" ID="C45804">nodes</Semaphore></Semaphore>, and right total <Semaphore x="2089953" class="AnatomicStructure" value="Knee Joint" score="1.00" ID="C32898">knee </Semaphore><Semaphore x="1547672" class="Procedure" value="Arthroplasty" score="1.00" ID="C51691">arthroplasty</Semaphore>. The subject's past medications included <Semaphore x="528270" class="Medicine" value="Enbrel" score="0.49" ID="248473">Enbrel </Semaphore>(<Semaphore x="545709" class="Medicine" value="Etanercept" score="0.49" ID="247557">etanercept</Semaphore>). His concomitant medications included <Semaphore x="596508" class="Medicine" value="Folic Acid" score="0.49" ID="268863">folic acid</Semaphore>, <Semaphore x="861252" class="Medicine" value="Methotrexate" score="0.49" ID="279493">methotrexate</Semaphore>, <Semaphore x="1243220" class="Medicine" value="Synthroid" score="0.49" ID="249232">Synthroid </Semaphore>(<Semaphore x="782363" class="Medicine" value="Levothyroxine Sodium" score="0.49" ID="266997">levothyroxine <Semaphore x="2536895" class="Procedure" value="Sodium Measurement" score="1.00" ID="C64809">sodium</Semaphore></Semaphore>) and <Semaphore x="1346638" class="Medicine" value="Vitamin D" score="0.49" ID="196852"><Semaphore x="2692307" class="Procedure" value="Vitamin D Measurement" score="1.00" ID="C84818">Vitamin D </Semaphore>(<Semaphore x="537604" class="Medicine" value="Ergocalciferol" score="0.49" ID="267015">ergocalciferol</Semaphore>).</Semaphore>The subject was initiated on <Semaphore x="360936" class="Medicine - Cimzia - Dose" value="400mg" score="0.49" ID=""><Semaphore x="360965" class="Medicine" value="Cimzia" score="0.74" ID="282644">Cimzia </Semaphore>(<Semaphore x="321298" class="Medicine - certolizumab pegol - Dose" value="400mg" score="0.49" ID=""><Semaphore x="321327" class="Medicine" value="certolizumab pegol" score="0.87" ID="281183">certolizumab pegol</Semaphore>) <Semaphore x="1379964402270210" class="Medicine - certolizumab pegol - Dose" value="400mg" score="0.49" ID="">400mg</Semaphore></Semaphore></Semaphore>
    <Semaphore x="1380028826779649" class="Medicine - certolizumab pegol - Frequency" value="," score="0.74" ID="">, </Semaphore>subcutaneous, once every two weeks since 12-May 2012 for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="2469205" class="Disease or Finding" value="Rheumatoid Arthritis" score="1.00" ID="C2884">rheumatoid arthritis </Semaphore>in the trial "CERTOL01_Solutions Pr Canada for <Semaphore x="2469205" class="Disease or Finding" value="Rheumatoid Arthritis" score="1.00" ID="C2884">rheumatoid arthritis</Semaphore>". From 16-Jun 2012, the dose of <Semaphore x="321298" class="Medicine - certolizumab pegol - Dose" value="400mg" score="0.49" ID=""><Semaphore x="321327" class="Medicine" value="certolizumab pegol" score="0.87" ID="281183">certolizumab pegol </Semaphore>was <Semaphore x="1379964402270209" class="Medicine - certolizumab pegol - Dose" value="200 mg" score="0.49" ID="">200 mg</Semaphore></Semaphore><Semaphore x="1380028826779649" class="Medicine - certolizumab pegol - Frequency" value="," score="0.74" ID="">, </Semaphore>subcutaneous, once every two weeks.The subject was seen by the <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>and noted <Semaphore x="2107425" class="Disease or Finding" value="Lesion" score="1.00" ID="C3824">lesions </Semaphore>on <Semaphore x="1405948" class="AnatomicStructure" value="Abdominal Wall" score="1.00" ID="C77608">abdominal wall</Semaphore>, under the <Semaphore x="2528100" class="AnatomicStructure" value="Skin" score="1.00" ID="C12470">skin</Semaphore>, in the fat; however not in the <Semaphore x="1405315" class="AnatomicStructure" value="Abdominal Cavity" score="1.00" ID="C12664">abdominal cavity</Semaphore>. The <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>suspected possible <Semaphore x="2477568" class="Disease or Finding" value="Sarcoma of the Orbit Clinical Distant Metastasis TNM Finding v7" score="1.00" ID="C88824">sarcoma </Semaphore>and/or <Semaphore x="2141674" class="Disease or Finding" value="Lymphoma" score="1.00" ID="C3208">lymphoma </Semaphore>(onset date 23-Oct 2012; moderate in intensity). The <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>performed ultrasound and <Semaphore x="1593910" class="Procedure" value="Biopsy" score="1.00" ID="C15189">biopsy </Semaphore>and states that the <Semaphore x="2266803" class="Disease or Finding" value="Neoplasm by Cause" score="1.00" ID="C27933">tumor </Semaphore>was inferior to the fat, 5 cm in diameter and protruding through belly. The <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>stated that the <Semaphore x="2266803" class="Disease or Finding" value="Neoplasm by Cause" score="1.00" ID="C27933">tumor </Semaphore>was <Semaphore x="2949378" class="MedDRA LLT" value="Fasting" score="1.00" ID="10068315">fast </Semaphore>growing as nothing was noted 3-4 weeks ago when the subject was last seen. The <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>expected the <Semaphore x="1593910" class="Procedure" value="Biopsy" score="1.00" ID="C15189">biopsy </Semaphore><Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results </Semaphore>within 5 days.At the time <Semaphore x="5960701642276866" class="" value="" score="" ID="">of report</Semaphore>, the events were ongoing and <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>with <Semaphore x="321327" class="Medicine" value="certolizumab pegol" score="0.87" ID="281183">certolizumab pegol </Semaphore>was continued.New relevant information was received by UCB on 16-Jan 2013 from the <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse</Semaphore>.The patient's final <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosis </Semaphore>was 'stage 1E <Semaphore x="1850969" class="Disease or Finding" value="Diffuse Large B-Cell Lymphoma" score="1.00" ID="C8851">diffuse large <Semaphore x="4906682308100097" class="" value="" score="" ID="">B <Semaphore x="2141438" class="Procedure" value="Lymphoma Cell Count" score="1.00" ID="C74613">cell </Semaphore></Semaphore>
      <Semaphore x="4906742437642241" class="" value="" score="" ID="">lymphoma</Semaphore></Semaphore>' (The previously reported events of suspected <Semaphore x="5569653459910657" class="" value="" score="" ID=""><Semaphore x="2141674" class="Disease or Finding" value="Lymphoma" score="1.00" ID="C3208">lymphoma </Semaphore>and </Semaphore><Semaphore x="5569713589452801" class="" value="" score="" ID="">suspected </Semaphore><Semaphore x="2477568" class="Disease or Finding" value="Sarcoma of the Orbit Clinical Distant Metastasis TNM Finding v7" score="1.00" ID="C88824">sarcoma </Semaphore>were <Semaphore x="2461946" class="Procedure" value="Replacement Of Lens" score="1.00" ID="C50836">replaced </Semaphore><Semaphore x="724848745644033" class="" value="" score="" ID="">with the </Semaphore><Semaphore x="724908875186177" class="" value="" score="" ID="">event </Semaphore>'stage 1E <Semaphore x="1850969" class="Disease or Finding" value="Diffuse Large B-Cell Lymphoma" score="1.00" ID="C8851">diffuse <Semaphore x="2239997243555841" class="" value="" score="" ID="">large B </Semaphore><Semaphore x="2141438" class="Procedure" value="Lymphoma Cell Count" score="1.00" ID="C74613"><Semaphore x="2240057373097985" class="" value="" score="" ID="">cell </Semaphore>lymphoma</Semaphore></Semaphore>'). The patient is having follow up at the hospital.</narrativeincludeclinical>
                <sendercomment>Elderly male subject with medical history of HLA B27 seronegative arthropathy and hypothyroidism experienced the event approximately 23 weeks after initiation of certolizumab pegol. The events had not resolved and therapy with certolizumab pegol was continued.</sendercomment>
            </summary>
        </patient>
    </safetyreport>
</ichicsr></original></faers>